Home/Filings/4/0000950170-24-021563
4//SEC Filing

MARCUS JOEL S 4

Accession 0000950170-24-021563

CIK 0001567514other

Filed

Feb 26, 7:00 PM ET

Accepted

Feb 27, 7:57 PM ET

Size

16.8 KB

Accession

0000950170-24-021563

Insider Transaction Report

Form 4
Period: 2024-02-26
Transactions
  • Exercise/Conversion

    Common Stock

    2024-02-26$55.48/sh+16,757$929,67865,990 total
  • Sale

    Common Stock

    2024-02-26$67.83/sh8,371$567,80557,619 total
  • Sale

    Common Stock

    2024-02-26$69.07/sh17,658$1,219,63839,961 total
  • Sale

    Common Stock

    2024-02-26$69.60/sh299$20,81039,662 total
  • Exercise/Conversion

    Common Stock

    2024-02-26$43.45/sh+20,000$869,00049,233 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2024-02-2620,0000 total
    Exercise: $43.45Exp: 2031-06-20Common Stock (20,000 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2024-02-2616,7570 total
    Exercise: $55.48Exp: 2032-06-08Common Stock (16,757 underlying)
Holdings
  • Common Stock

    (indirect: See Footnote)
    10,000
Footnotes (5)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.53 to $68.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.53 to $69.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.53 to $69.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  • [F4]Represents securities held of record by Alexandria Real Estate Equities, Inc. The reporting person is the Executive Chairman & Founder of Alexandria Real Estate Equities, Inc. and may therefore be deemed to have voting and investment power with respect to the shares owned by Alexandria Real Estate Equities, Inc. The reporting person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
  • [F5]All shares underlying this option have vested.

Documents

1 file

Issuer

Intra-Cellular Therapies, Inc.

CIK 0001567514

Entity typeother

Related Parties

1
  • filerCIK 0001216955

Filing Metadata

Form type
4
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 7:57 PM ET
Size
16.8 KB